Aim High Investment Group LLC v. Spectrum Laboratories, LLC

District Court, D. Nevada·Decided March 12, 2024·No. 2:22-cv-00158·Unknown

Opinion

1 UNITED STATES DISTRICT COURT

2 DISTRICT OF NEVADA 3

4 AIM HIGH INVESTMENT GROUP, LLC, ) ) Case No.: 2:22-cv-00158-GMN-DJA 5 Plaintiff, ) 6 vs. ) ) 7 SPECTRUM LABORATORIES, LLC, ) ORDER DENYING ) AIM HIGH’S OBJECTION 8 Defendant. ) ) 9 ) 10 SPECTRUM LABORATORIES, LLC, ) ) 11 Counter-Claimant, ) vs. ) 12 ) 13 AIM HIGH INVESTMENT GROUP, LLC, ) ) 14 Counter-Defendant. ) ) 15 16 Pending before the Court is Plaintiff and Counter-Defendant Aim High Investment 17 Group’s (“Aim High’s”) Objection/Appeal, (ECF No. 93), to the Magistrate Judge’s Order, 18 (ECF No. 90), denying Aim High’s Motion to Supplement its noninfringement and invalidity 19 contentions, (ECF No. 58). Defendant and Counter-Claimant Spectrum Laboratories 20 (“Spectrum”) filed a Response, (ECF No. 94), to the Objection. 21 Also pending before the Court is Spectrum’s Unopposed Motion for Extension of Time 22 to respond to Aim High’s Objection. (ECF No. 95).1 23

24 1 Aim High did not file a response to Spectrum’s Motion, and the deadline to do so has passed. “The failure of an opposing 25 party to file points and authorities in response to any motion, except a motion under Fed. R. Civ. P. 56 or a motion for attorney’s fees, constitutes a consent to the granting of the motion.” LR 7-2(d). Accordingly, the Court GRANTS the Motion as unopposed nunc pro tunc. 1 The Court DENIES Aim High’s Objection because Aim High fails to establish that the 2 Magistrate Judge’s Order was clearly erroneous or contrary to law. 3 I. BACKGROUND 4 This action arises from a patent infringement dispute based on Spectrum’s patented 5 synthetic urine formulas. (See generally Compl., ECF No. 1). The patents involve a formula 6 containing biocides added to minimize bacteria growth in the mixture, thus preserving the shelf 7 life of the synthetic urine. (Id. ¶ 2). Before litigation began, Spectrum sent a letter to Aim High 8 alleging that the XStream product infringed two of its Patents. (Id. ¶ 11). In response, Aim 9 High denied the allegation and requested lab tests demonstrating infringement. 10 (Correspondence, Exs. A–C to Resp. to Mot. Compel, ECF Nos. 51-1, 51-2, 51-3). Spectrum 11 provided a redacted report from S&N Laboratories, stating that the report was disclosed 12 “without any waiver of privilege or work-product.” (Confidential Letter, Ex. D to Resp. Mot. 13 Compel, ECF No. 51-4). Aim High challenged the authenticity of the report, so Spectrum sent 14 Aim High a report from a second lab, Element Laboratories. (Letter and Element Report, Ex. 2 15 to Mot Compel, ECF No. 45-3). Aim High reviewed the correspondence and lab reports, and 16 then brought a claim for declaratory judgment that its XStream product does not infringe on 17 Spectrum’s patents. (Compl. ¶ 1). Spectrum counter-claimed for injunctive relief and damages, 18 alleging that Aim High’s XStream product infringed on its Patents. (Counterclaim, ECF No. 7). 19 On May 13, 2022, Aim High served written discovery requests on Spectrum, and issued 20 subpoenas to the California labs. (Mot. Leave 3:24–28, ECF No. 58); (Subpoenas, Exs. 9–10 to 21 Resp. to Mot. Compel, ECF Nos. 51-9, 51-10). Spectrum and the labs objected on work- 22 product grounds, so Aim High moved to compel. (Opp. to CA Mot. Compel, Ex. 10 to Mot. 23 Compel, ECF No. 45-11); (CA Mot. Compel, Ex. 9 to Mot. Compel, ECF No. 45-10). On 24 October 20, 2022, the California Magistrate Judge denied Aim High’s Motion to Compel the

25 1 labs to produce their testing reports. (See generally Order, Ex. 12 to Mot. Compel, ECF No. 45- 2 13). Aim High filed an objection. (CA Obj. at 2, Ex. 13 to Mot. Compel, ECF No 45-14). 3 A. Claim Construction Briefing 4 During the same time period, the parties began claim construction briefing. Spectrum 5 filed its opening brief on August 24, 2022, Aim High filed its brief a couple weeks later, and 6 Spectrum filed its Reply on September 21. (Spectrum Opening Brief, ECF No. 32); (Aim High 7 Brief, ECF No. 33); (Spectrum Reply Brief, ECF No. 43). Following the conclusion of claim 8 construction briefing and after the California Magistrate Judge’s denial of Aim High’s Motion 9 to Compel the lab reports, Aim High hired new patent counsel who commissioned a prior art 10 search on November 9, 2022. (Smith Decl. ¶¶ 3–4, Ex. 1 to Mot. Leave, ECF No. 58-2). Aim 11 High received the search results on November 23, 2022. (Id. ¶ 5). After reviewing the prior art 12 found in the search, Aim High emailed Spectrum a month later to inform Spectrum of its intent 13 to move for leave to supplement its invalidity contentions. (Intent Email, Ex. 8 to Mot. Leave, 14 ECF No. 58-9). Aim High created claim charts explaining its new invalidity contentions based 15 on the prior art and emailed the charts to Spectrum on January 24, 2023. (Chart Email, Ex. 11 16 to Mot. Compel, ECF No. 58-12). When Spectrum did not stipulate, Aim High filed its Motion 17 for Leave to Amend on February 17, 2023. 18 Aim High’s Motion for Leave seeks to supplement its non-infringement and invalidity 19 contentions to include additional invalidity claims based on the prior art that its new counsel 20 discovered. (Mot. Leave 7:7–8:17); (Obj. to MJ Order 5:26–6:9, ECF No. 93). Aim High also 21 sought to add additional details to defenses based on Spectrum’s claim construction briefs. 22 (Obj. to MJ Order 6:5–9). At the time Aim High filed its Motion for Leave, the Court had not 23 yet scheduled a claim construction hearing and discovery was set to close in three months. 24 ///

25 /// 1 B. Underlying Magistrate Judge Order 2 Magistrate Judge Albregts denied Aim High’s Motion for Leave on the grounds that 3 Aim High did not demonstrate good cause and that amendment would cause Spectrum to be 4 unduly prejudiced. (MJ Order, ECF No. 90). A party who wishes to amend its disclosures 5 under LPR 1-12, such as Aim High, must: (1) first obtain the Court’s leave; (2) show good 6 cause for the requested amendment; (3) demonstrate it acted diligently; and (4) show the other 7 party would not be “unfairly prejudiced by ‘eleventh hour alterations.’” See LPR 1-12; see 8 Silver State Intellectual Techs., Inc. v. Garmin Int’l, Inc., 32 F. Supp. 3d 1155, 1162 (D. Nev. 9 2014). 10 Beginning with the good cause analysis, the Magistrate Judge acknowledged that it was 11 a close call, but focused on the timeline and substance of the amendment to reach his 12 conclusion that Aim High was not diligent and lacked good cause to amend. (MJ Order 4:20– 13 22). Though Aim High asserted that Spectrum’s refusal to allow discovery of the lab reports 14 contributed to its decision to conduct a second prior art search, Spectrum’s objection was filed 15 in June of 2022, and the second prior art search was not until November. (Id. 4:24–5:2). He 16 found that while the delay could be explained by the California Magistrate Judge’s denial of 17 Aim High’s Motion to Compel on October 20, 2022, Aim High did not sufficiently make that 18 argument. (Id. 5:3–10). The Magistrate Judge further stated that Aim High had not explained 19 why the denial of lab report discovery necessitated another prior art search. (Id. 5:10–13). 20 Magistrate Judge Albregts came to a similar conclusion on Aim High’s argument that 21 Spectrum’s claim construction position on the term “biocide” further necessitated a second 22 prior art search. (Id. 5:14–26). Spectrum filed its opening claim construction brief on August 23 24, 2022, two and a half months before the commission of Aim High’s prior art search, and 24 four and a half months before Aim High informed Spectrum of its intent to amend. (Id.). The

Free access — add to your briefcase to read the full text and ask questions with AI

Aim High Investment Group LLC v. Spectrum Laboratories, LLC, (D. Nev. 2024).

Aim High Investment Group LLC v. Spectrum Laboratories, LLC (Aim High Investment Group LLC v. Spectrum Laboratories, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related